Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

British Journal of Cancer

Volumn 101, Issue 1, 2009, Pages 32-37

  Armaou, S ^a   Pertesi, M ^a   Fostira, F ^a   Thodi, G ^a   Athanasopoulos, P S ^a   Kamakari, S ^b   Athanasiou, A ^c   Gogas, H ^d   Yannoukakos, D ^a   Fountzilas, G ^e,f   Konstantopoulou, I ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b Biogenomica Laboratory   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f Hellenic Cooperative Oncology Group   (Greece)

Author keywords

BRCA1; BRCA2; Founder mutation; Genetic screening; Germ line mutation; Hereditary breast ovarian cancer

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER FAMILY; CONTROLLED STUDY; ETHNIC GROUP; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERM LINE; GREECE; HETEROZYGOTE; HOSPITAL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; AGED; BREAST TUMOR; GENETICS; MIDDLE AGED; MUTATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EXONS; FEMALE; GENE DELETION; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; GREECE; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 67649866244     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605115     Document Type: Article

References (41)

1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505-514
2. Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, Athanasiou A, Dobrovic A, Young MA, Goldgar D, Fountzilas G, Yannoukakos D (2008) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat 110: 377-385
3. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83: 1301 - 1308
4. Armaou S, Konstantopoulou I, Anagnostopoulos T, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D (2007) Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. Eur J Cancer 43: 443 - 453
5. Backe J, Hofferbert S, Skawran B, Dork T, Stuhrmann M, Karstens JH, Untch M, Meindl A, Burgemeister R, Chang-Claude J, Weber BH (1999) Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 72: 402-406
6. Bermisheva MA, Zinnamullina GF, Gantsev S, Kochanova VA, Popov OS, Dork T, Khusnutdinova EK (2008) [Frequency of 5382insC mutation of the BRCA1 gene]. Vopr Onkol 54: 31-33
7. Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Bremond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, Leone M, Chauvin F, Easton DF, Lenoir GM, Lasset C (2005) Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 43: 404-413
8. Chan PC, Wong BY, Ozcelik H, Cole DE (1999) Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR. Clin Chem 45: 1285 - 1287
9. da Costa EC, Vargas FR, Moreira AS, Lourenco JJ, Caleffi M, Ashton-Prolla P, Martins Moreira MA (2008) Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet 184: 62-66
10. De Greve J, Sermijn E, De Brakeleer S, Ren Z, Teugels E (2008) Hereditary breast cancer: from bench to bedside. Curr Opin Oncol 20: 605 - 613
11. de Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 106: 588-593
12. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev 7: 937 - 948
13. Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6): vi93-vi98
14. Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103: 349- 353
15. Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbanski K, Mitus J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Toloczko-Grabarek A, Medrek K, Masojc B, Mierzejewski M, Kowalska E, Narod SA, Lubinski J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92: 19-24
16. Hamel N FL, Narod SA, Tihomirova L, Zajac V, Ciernikova S, Armaou S, Yannoukakos D, Greenwood C, Foulkes WD (2006) Investigating the origins of the BRCA1 mutation c.5385dupC. In: Abstracts of the 56th Annual Meeting of the American Society of Human Genetics. New Orleans, LA, USA. 203
17. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298: 2869 - 2876
18. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643 - 646
19. Konstantopoulou I, Rampias T, Ladopoulou A, Koutsodontis G, Armaou S, Anagnostopoulos T, Nikolopoulos G, Kamakari S, Nounesis G, Stylianakis A, Karanikiotis C, Razis E, Gogas H, Keramopoulos A, Gaki V, Markopoulos C, Skarlos D, Pandis N, Bei T, Arzimanoglou I, Fountzilas G, Yannoukakos D (2008) Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 107: 431-441
20. Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D (2002) Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett 185: 61 - 70
21. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93: 1215 - 1223
22. Lubinski J, Gorski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernandez P, Domagala W, Chosia M, Ucinski M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J,Mierzwa T,Niepsuj S,Gugala K, Gozdz S, Sygut J, Kozak-Klonowska B,Musiatowicz B, Posmyk M, Kordek R, Morawiec M, Zambrano O, Wasko B, Fudali L, Skret J, Surdyka D, Urbanski K, Mitus J, Rys J, Szwiec M, Rozmiarek A, Dziuba I, Wandzel P, Wisniowski R, Szczylik C, Kozak A, Kozlowski W, Narod SA (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99: 71 - 76
23. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL,Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66: 8297 - 8308
24. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA (2000) Frequency of BRCA1/ BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88: 1393 - 1402
25. Margolin S, Werelius B, Fornander T, Lindblom A (2004) BRCA1 mutations in a population-based study ofbreast cancer in Stockholm County. Genet Test 8: 127 - 132
26. Neuhausen SL (2000) Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2: 77 - 81
27. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58: 271 - 280
28. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279: 915-921
29. Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges- Cardwell J, Mason BA, Rebbeck TR, Nathanson KL (2008) The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 68: 7006 - 7014
30. Papelard H, de Bock GH, van Eijk R, Vliet Vlieland TP, Cornelisse CJ, Devilee P, Tollenaar RA (2000) Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83: 719-724
31. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
32. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943-949
33. Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. New Engl J Med 357: 154- 162
34. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 10: 467-473
35. Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, Weber BL (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6: 4259 - 4264
36. Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, Kuligina E, Ulibina YM, Rozanov ME, Suspitsin EN, Matsko DE, Chagunava OL, Trofimov DY, Devilee P, Cornelisse C, Togo AV, Semiglazov VF, Imyanitov EN (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42: 1380- 1384
37. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529-1531
38. Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60: 1013-1020
39. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE (1998) Population- based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352: 1337- 1339
40. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11: 103- 105
41. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91: 1241 - 1247